Atrium Therapeutics Reports Quarterly Results for Quarter Ended June 30, 2026

What Happened

• On August 13, 2026, Atrium Therapeutics, Inc. (RNA) announced its financial results for the quarter ended June 30, 2026 and filed a Current Report on Form 8-K (Item 2.02).
• The company furnished the full text of the press release reporting those results as Exhibit 99.1 to the Form 8-K.

Key Details

• Filing date: August 13, 2026.
• Reporting period: quarter ended June 30, 2026.
• Form 8-K items reported: Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Exhibits) — Exhibit 99.1 is the press release.
• The press release text is furnished with the 8-K; investors should consult that exhibit for specific financial figures and commentary.

Why It Matters

• This 8-K notifies investors that Atrium has released its quarterly earnings information — a material update that can affect the stock and investor decisions.
• Because the Form 8-K itself furnishes the press release but does not include the numbers in the filing text, retail investors should review Exhibit 99.1 and any accompanying investor materials or SEC filings for revenue, net income/loss, guidance, and management commentary before making decisions.